That seems highly unlikely since milestone 19, listed below, is going to occur between Q2-Q4 2022. A year + away. So FDA late 2022 or early 2023 if all stays on track per their development table.
Milestone 16
Complete IDE clinical study, data analysis and final report
Now that they have IDE approval, they need to complete the investigation and request market approval. I think the timing for that may align with milestone 4, but not certain.